steatohepatitis


Also found in: Dictionary, Wikipedia.
Related to steatohepatitis: fatty liver, cirrhosis, Alcoholic Steatohepatitis

ste·a·to·hep·a·ti·tis

(stē'ă-tō-hep'ă-tī'tis),
Liver disease characterized by fatty change of hepatocytes, accompanied by intralobular inflammation and fibrosis; diagnozed microscopically in biopsy or autopsy specimens. Most often caused by alcohol abuse, diabetes, or obesity but may be linked to adverse drug reactions, gastrointestinal and pancreatic disorders or total parenteral nutrition. See NASH
See also: NASH.
[steato- + hepatitis]

steatohepatitis

A generic term for a fatty liver; with time, patients with steatohepatitis develop portal changes including interface hepatitis, increased portal inflammation and fibrosis, and ductular reaction. Some cases arise in a background of haemochromatosis.
References in periodicals archive ?
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).
The "Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights, Trends and Forecast (2019-2028)" report has been added to ResearchAndMarkets.com's offering.
Based on its central metabolic role, targeting AMPK offers the opportunity to pursue a wide range of indications to treat chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis.
It is likely to decrease liver cell injury and also hepatic inflammation through resolution of steatohepatitis. The partnership integrates Yuhan's expertise in FGF21 biology, obesity and NASH, with the pharmaceutical expertise and commitment of Boehringer Ingelheim to develop drugs for cardiometabolic diseases.
Present study was undertaken in 60 patients to assess the biochemical profile and various treatment modalities of patients with non-alcoholic steatohepatitis. Out of which 28 (46.66%) were males and 32 (53.32%) were females.
The partnership has generated several early drug discovery targets shown to inhibit biological processes associated with inflammation and fibrosis that can lead to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer.
[45] demonstrated that TLR2-deficient mice are resistant to diet-induced steatohepatitis, showing a lower expression of proinflammatory cytokines (TNF[alpha] and IL-1[beta]) [46].
Maryland Heights, MO, May 06, 2017 --(PR.com)-- Non-alcoholic Steatohepatitis or Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that may cause hepatic inflammation and progressive scarring leading to nonalcoholic steatohepatitis (NASH) and irreversible liver damage (cirrhosis).
A multimodal research process has provided clues to the role of angiogenesis in the etiology of nonalcoholic fatty liver disease (NAFLD) and its more serious cousin, nonalcoholic steatohepatitis (NASH).
Fatty liver is a leading step to chronic liver diseases including steatohepatitis (nonalcoholic steatohepatitis, NASH, and alcoholic steatohepatitis, ASH), liver fibrosis, and cirrhosis worldwide [4].
Long-term pioglitazone is not only safe for patients with non-alcoholic steatohepatitis and prediabetes or type 2 diabetes but may be associated with significant improvements in fatty liver disease outcomes, compared with placebo, a study showed.